accountFRANKFURT -(Dow Jones)- Bayer AG (BAYN.XE) said Sunday it won't provide a complete response to the U.S. Food and Drug Administration on its anti-coagulant Rivaroxaban by year-end but will issue an...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Bayer To Communicate Rivaroxaban Filing Strategy Update In Feb
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account